Epoetin Alfa Dosing and Administration Guidelines

Dosing Considerations

• Subcutaneous administration of epoetin alfa is 15-50% more efficient than intravenous administration, requiring lower doses, as reported by the American Journal of Kidney Diseases 1, 2
• The target hemoglobin level for cancer patients should not exceed 12 g/dL, according to guidelines supported by Blood 3, 4

Iron Supplementation and Monitoring

• Iron status should be evaluated before and during epoetin alfa treatment, with a goal of maintaining transferrin saturation >20% and serum ferritin >100 μg/L, as recommended by Blood 3, 4

Special Considerations

• When switching from intravenous to subcutaneous administration of epoetin alfa, the weekly dose should be reduced to two-thirds of the intravenous dose, as suggested by the American Journal of Kidney Diseases 2
• Rotation of injection sites is recommended to minimize local reactions, as advised by the American Journal of Kidney Diseases 1

Non-Response Evaluation

• In cases of inadequate response to epoetin alfa, potential causes such as iron deficiency, infection or inflammation, blood loss or hemolysis, tumor progression, and development of antibodies to erythropoietin should be evaluated, as recommended by Blood 3, 4